Education for Multiple Myeloma

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Dartmouth-Hitchcock Medical Center, Lebanon, NH
Multiple Myeloma+7 More
Education - Behavioral
Eligibility
18+
All Sexes
Eligible conditions
Select

Study Summary

This study is evaluating whether a brief educational visit can help improve emotional stressors for individuals who have undergone a stem cell transplant.

See full description

Eligible Conditions

  • Multiple Myeloma
  • Lymphoma
  • Haematopoietic stem cell transplant
  • Hematopoietic Stem Cell Transplantation (SCT)
  • Cellular Therapy
  • CAR-T Cell Therapy
  • CAR T-Cell Transplant
  • Leukemia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

This trial is evaluating whether Education will improve 2 primary outcomes and 2 secondary outcomes in patients with Multiple Myeloma. Measurement will happen over the course of Day 0 (date cells are infused) to 12-months post-transplant.

12-months post-transplant
Overall Survival
Baseline (pre-transplant) and 1, 3, 6, and 12-months post-transplant/CAR-T
Change in levels of anxiety, depression, and fatigue as measured by NCCN Distress Thermometer
Change in levels of anxiety, depression, and fatigue as measured by PROMIS-29
Day 0
Post-Transplant Complications

Trial Safety

Trial Design

1 Treatment Group

Education Group
1 of 1
Experimental Treatment

This trial requires 30 total participants across 1 different treatment group

This trial involves a single treatment. Education is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Education Group
Behavioral
Participants will receive an educational intervention focusing on psychosocial stressors and timeline of symptoms associated with the transplant/CAR-T experience.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Education
2017
Completed Phase 3
~4010

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline (pre-transplant) and 1, 3, 6, and 12-months post-transplant/car-t
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly baseline (pre-transplant) and 1, 3, 6, and 12-months post-transplant/car-t for reporting.

Who is running the study

Principal Investigator
K. M.
Kenneth Meehan, Staff Physician
Dartmouth-Hitchcock Medical Center

Closest Location

Dartmouth-Hitchcock Medical Center - Lebanon, NH

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 4 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
Any patient with an underlying hematologic disease planning to undergo an autologous or allogeneic hematopoietic stem cell transplant (HSCT) or chimeric antigen receptor T-cell (CAR-T) therapy at Dartmouth-Hitchcock Medical Center is eligible.
The patient must be approved for HSCT/CAR-T by the treating transplant physician.
This includes completion of their pre-treatment work up and consent as directed by the standard DHMC SOPs.
- Age >18 years, and no upper age limit

Patient Q&A Section

What are common treatments for multiple myeloma?

"The most common treatments for primary multiple myeloma include supportive care and drug regimens; they are usually based on the age of the patient. Treatment regimens including corticosteroids, bortezomib, or autophagy inhibitors are not available in most jurisdictions and may only benefit a small fraction of cases. Although multiple myeloma can often be treated over one to two years in first disease, most patients will have a relapse in the subsequent years." - Anonymous Online Contributor

Unverified Answer

What are the signs of multiple myeloma?

"The signs of [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) include bone pain and an unfavourable attitude, but the most specific sign of multiple myeloma is plasma cell dyscrasia. It may therefore be necessary to investigate for multiple myeloma whenever an unresponsive myeloma patient has a plasma cell phenotype. Multiple myeloma patients may be misdiagnosed as a case of autoimmune diabetes in the elderly or another autoimmune disease if signs are restricted to high-dose glucocorticoid treatment." - Anonymous Online Contributor

Unverified Answer

How many people get multiple myeloma a year in the United States?

"Approximately 20,000 new cases of MM are diagnosed a year in the United States. question: Does low vitamin D status predict the progression from IgA1 nephropathy to proliferative lupus nephritis? answer: Data from a recent study reveals that vitamin D is associated with the progression from IgA1N to PMLN. Vitamin D levels are not associated with the development of IgA1N to IgAN. Further studies are needed to investigate the usefulness of vitamin D supplements for the prevention of PMLN." - Anonymous Online Contributor

Unverified Answer

What is multiple myeloma?

"Although the incidence of MM in the United States has increased 10-fold over the last 45 years, survival has maintained a trend toward improvement, likely because of the development of more effective and more frequent treatment options and improved control of MM-related hematologic manifestations." - Anonymous Online Contributor

Unverified Answer

Can multiple myeloma be cured?

"While some of our patients had very minimal and mild, yet still present, clinical response to bortezomib treatment, no patients ever had a complete remission or complete responses. Some patients had progressive disease with a response to bortezomib and then subsequent rapid progression of disease thereafter. As with all antitumor agents, careful patient selection before beginning treatment as well as follow up during treatment are important to minimize any effects of therapy on disease progression. We also noted in some patients a very short follow-up interval and thus limited insight regarding prolonged responses to bortezomib. Long-term studies are necessary to clarify its role in treating multiple myeloma." - Anonymous Online Contributor

Unverified Answer

What causes multiple myeloma?

"The exact causes are unknown, but it is known to be related to genetic factors and cancer. As more people with myeloma survive a diagnosis of multiple myeloma is often the result." - Anonymous Online Contributor

Unverified Answer

What are the common side effects of education?

"[Education is a highly successful intervention for a variety of health conditions such as coronary heart disease, stroke, cancer, diabetes and osteoarthritis, because it improves knowledge and attitudes, improves self-care, improves adherence with treatment, and leads to behavioral improvements (http://www.ncommsnet.org/content/article/1/4_cite." - Anonymous Online Contributor

Unverified Answer

What is the latest research for multiple myeloma?

"Patients with [multiple myeloma](https://www.withpower.com/clinical-trials/multiple-myeloma) have a better quality of life following treatment. There is evidence that exercise in multiple myeloma patients can provide benefit for quality of life and that this might have clinical implications. There is still little research available on the effect of exercise on survival in this disease. There is however a clear need for research, particularly for exercise training interventions with myeloma patients." - Anonymous Online Contributor

Unverified Answer

What is the average age someone gets multiple myeloma?

"In the US, multiple myeloma occurs mainly in the aged; only around 0.5 to 1.0% of all people are under age 60. In Europe, the age at diagnosis of multiple myeloma has shifted since 1990 to earlier ages (56-60 years, as of 2009 at the age of diagnosis, up from 35 years during the 1970s-1980s), and is now similar to the incidence reported in Canada (2009)." - Anonymous Online Contributor

Unverified Answer

Does education improve quality of life for those with multiple myeloma?

"Improving quality of life in patients with MM requires an effective plan tailored to each individual patient. The addition of education to standard palliative care interventions in this setting does not improve quality of life. Given that health beliefs can affect patients' quality of life, interventions that address patients' beliefs and attitudes to care may be more effective in improving the quality of life of individuals with MM." - Anonymous Online Contributor

Unverified Answer

What is the survival rate for multiple myeloma?

"Patients diagnosed with MM have been consistently associated with earlier ages of presentation and more aggressive disease at diagnosis, and also shorter overall survival. MM tends to occur more frequently in older males, thus male and female MM incidence rates are relatively equal. MM is also less often diagnosed among African Americans compared with other ethnicities." - Anonymous Online Contributor

Unverified Answer

Is education safe for people?

"In a large group of people undergoing an elective elective surgical procedure, education alone did not reduce morbidity or complications. However, this study cannot refute the important benefits education may have on patient's comprehension, adherence and satisfaction at the time of any procedure. Further evaluations are now required to establish the full implications of education for the health of patients." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
See if you qualify for this trial
Get access to this novel treatment for Multiple Myeloma by sharing your contact details with the study coordinator.